Pj. Hollen et al., QUALITY-OF-LIFE DURING CLINICAL-TRIALS - CONCEPTUAL-MODEL FOR THE LUNG-CANCER SYMPTOM SCALE (LCSS), Supportive care in cancer, 2(4), 1994, pp. 213-222
Citations number
43
Categorie Soggetti
Oncology,Rehabilitation,"Medicine, General & Internal
To appreciate the full benefits of treatment for lung cancer, especial
ly in trials that fail to show improvements in survival, data recordin
g the quality of life must be captured and refined to produce meaningf
ul information. A conceptual model for quality of life for lung cancer
patients was tested to obtain information about the dimensions of the
quality-of-life construct for ongoing development and testing of a su
bjective measure for clinical trials. Using a longitudinal study desig
n, the stability of predictive factors of the physical and functional
dimensions of quality of life were examined using regression analysis.
A patient-rated quality-of-life measure, the Lung Cancer Symptom Scal
e (LCSS), was administered to 144 non-small-cell lung-cancer patients
at baseline, day 29, and day 71 of a chemotherapy trial. The range bf
explained variance for all three components of the lung cancer model o
ver three assessment points was as follows: symptomatic distress 41%-5
3%, activity status 48%-52%, and overall quality of life 35%-53%. The
three dimensions fluctuated slightly during intervention. but were rel
atively stable factors across all three times of evaluation. The LCSS
model explained nearly half of the variance for quality of life experi
enced by lung cancer patients during therapy with a new chemotherapeut
ic agent. These findings provide support that the physical and functio
nal dimensions are important predictors of quality of life for individ
uals with lung cancer. Meaningful subjective quality-of-life data can
be obtained to evaluate an intervention by using a disease- and site-s
pecific quality-of-life measure for individuals with lung cancer, base
d on a reproducible conceptual model such as the LCSS, which is suitab
le for serial measurement for the progressive disease of lung cancer.